Bibliografia | Iberogast®
  1. Kelber, O ., F . Gaedcke, B . Steinhoff and H . Winterhoff “Ethanol in herbal medicinal products for children .” PharmInd, 2008 . 70(9): 1124–7 .
  2. Pilichiewicz, A . N ., M . Horowitz, G . J . Holtmann, N . J . Talley and C . Feinle-Bisset "Relationship between symptoms and dietary patterns in patients with functional dyspepsia ." Clin Gastroenterol Hepatol, 2009 . 7(3): 317-22 .
  3. von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .
  4. Abdel-Aziz, H ., M . Schneider, W . Neuhuber, A . M . Kassem, S . Khailah, J . Muller, H . Gamaleldeen, A . Khairy, M . T . Khayyal, A . Shcherbakova, T . Efferth and G . Ulrich-Merzenich “GPR84 and TREM-1 signaling contribute to the pathogenesis of reflux esophagitis .” Mol Med, 2015 . 21(1): 1011–1024 .
  5. Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast .” Planta Med, 2017 . 83(14/15): 1130–1140 .
  6. Adarsh, M . B ., S . K . Sharma, K . K . Prasad, V . Dhir, S . Singh and S . K . Sinha " Esophageal manometry, esophagogastroduodenoscopy, and duodenal mucosal histopathology in systemic sclerosis ." JGH Open, 2019 . 3(3): 206-209 .
  7. Allam, S ., D . Krueger, I . E . Demir, G . Ceyhan, F . Zeller and M . Schemann “Extracts from peppermint leaves, lemon balm leaves and in particular angelica roots mimic the pro-secretory action of the herbal preparation STW 5 in the human intestine .” Phytomedicine, 2015 . 22(12): 1063–1070 .
  8. Allescher, H . D . and H . Abdel-Aziz “Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target .” Dig Dis, 2017 . 35 (Suppl 1): 18–24 .
  9. Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy ." Phytomed, 2006. 13 SV 2-11
  10. Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy ." Phytomedicine, 2006. 13 SV 2-11 .
  11. Ammon, H . P ., O . Kelber and S . N . Okpanyi “Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle .” Phytomedicine, 2006 . 13 (Suppl 5): 67–74 .
  12. Angelicae radix, ESCOP monographs 2009.
  13. Anisi Fructus, ESCOP monographs 2014 .
  14. Annibale. B ., G . Esposito and E . Lahner " A current clinical overview of atrophic gastritis ." Expert Rev Gastroenterol Hepatol, 2020 . 14(2): 93-102 .
  15. Balaban, C . D . and B . J . Yates "What is nausea? A historical analysis of changing views ." Auton Neurosci, 2017 . 202: 5-17 .
  16. Berg, L . K ., E . Fagerli, M . Martinussen, A . O . Myhre, J . Florholmen and R . Goll "Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test ." Scand J Gastroenterol, 2013 . 48(8): 936-43 .
  17. Bhatia, V . and R . K . Tandon "Stress and the gastrointestinal tract ." J Gastroenterol Hepatol, 2005 . 20(3): 332-9 .
  18. Bleimann, H ., R . Hartmann "Therapy of Gastrointestinal Functional Disorders with Iberogast ." Der Kassenarzt, 1983; 23:52-59 .
  19. Boeckxstaens, G ., M . Camilleri, D . Sifrim, L . A . Houghton, S . Elsenbruch, G . Lindberg, F . Azpiroz and H . P . Parkman "Fundamentals of Neurogastroenterology: Physiology/Motility – Sensation ." Gastroenterology, 2016 . 150: 1292-1304 .
  20. Boland, M . "Human digestion - a processing perspective ." J Sci Food Agric, 2016 . 96: 2275-283 .
  21. Bonaterra, G . A ., O . Kelber, D . Weiser and R . Kinscherf “Mechanisms of the antiproliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast®) on colon adenocarcinoma (HT29) cells in vitro .” Phytomedicine, 2013 . 20(8–9): 691–698 .
  22. Bonaterra, G ., R . Kinscherf, O . Kelber, D . Weiser and J . Metz “Antiinflammatorische und antiproliferative Wirkung von Iberogast® in vitro .” Z Gastroenterol, 2008 . 46(09): P352 .
  23. Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625 .
  24. Bredenoord, A . J . and A . J . P . Smout "Physiologic and pathologic belching ." Clin Gastroenterol Hepatol, 2007 . 5(7): 772-5 .
  25. Bremer, W ., F . Fischer and K . Nicolay "Gastrointestinal Illnesses - Therapy with Iberogast® " Z. Allg. Med., 1983 . 59: 1706-1709 .
  26. Brückel, M . H ., W . Gisevius "Iberis Amara Helps in Cases of Functional Stomach Complaints ." Ärztl. Praxis, 1984 . 36: 494 .
  27. Brun, R . and B . Kuo “Functional dyspepsia .” Therap Adv Gastroenterol, 2010 . 3(3):145–164 .
  28. Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .
  29. Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .
  30. Burns, L . M . “Oral (gavage) developmental toxicity dose range finding study in the rabbit .” 2003 . Sequani Study no: VEB0003 .
  31. Burns, L . M . “Oral (gavage) developmental toxicity dose range finding study in the rat .” 2003 . Sequani Study no: VEB0006 [Module 4 .2 .3 .5 .1 .3] .
  32. Burns, L . M . “Oral (gavage) developmental toxicity study in the rabbit .” 2003 . Sequani Study no: VEB0004 .
  33. Burns, L . M . “Oral (gavage) developmental toxicity study in the rat .” 2003 . Sequani Study no: VEB0008 [Module 4 .2 .3 .5 .1 .2] .
  34. Burns, L . M . “Oral (gavage) fertility and early embryonic development study in the rat .” 2003 . Sequani Study no: VEB0007 [Module 4 .2 .3 .5 .1 .4] .
  35. Burns, L . M . “Oral (gavage) fertility and general reproductive performance dose ranging study in the rat .” 2003 . Sequani Study no: VEB0005 [Module 4 .2 .3 .5 .1 .1] .
  36. Burns, L . M . “Oral (gavage) maximum tolerated dose (MTD) study in the rabbit .” 2003 . Sequani Study no: VEB0002 .
  37. Burns, L . M . “Oral (gavage) pre- and post-natal developmental toxicity study in the rat .” 2003 . Study no: VEB0009 [Module 4 .2 .3 .5 .3 .1] .
  38. Burri, E ., E . Barba, J . W . Huaman, D . Cisternas, A . Accarino, A . Soldevilla, J . R . Malagelada, and F . Azpiroz "Mechanisms of postprandial abdominal bloating and distension in functional dyspepsia ." Gut, 2014 . 63(3): 395-400 .
  39. Bustos, M ., R . Venkataramanan and Steve Caritis "Nausea and vomiting of pregnancy - What's new? " Auton Neurosci, 2017. 202: 62-72 .
  40. Bytzer, P . and N . J . Talley “Dyspepsia .” Ann Intern Med, 2001 . 134(9 Pt 2): 815–822 .
  41. Camilleri, M ., B . Coulie and J . F . Tack “Visceral hypersensitivity: facts, speculations, and challenges .” Gut, 2001 . 48(1): 125–131 .
  42. Carvalho, R . V . B ., S . L . S . Lorena, J . R . de Souza Almeida and M . A . Mesquita "Food intolerance, diet composition, and eating patterns in functional dyspepsia patients ." Dig Dis Sci, 2010 . 55(1): 60-5 .
  43. Carvi fructus, ESCOP monographs 2003.
  44. Catassi, G ., E . Lionetti, S . Gatti and C . Catassi "The Low FODMAP Diet: Many Question Marks for a Catchy Acronym ." Nutrients, 2017 . 9(3): 292 .
  45. Company Core Data Sheet Iberogast, Version 03 from Nov, 2 2018 .
  46. Csef, H . “Funktionelle (somatoforme) Störungen beim internistischen Hausbesuch .” Internist, 2001 . 42: 1476 .
  47. De Giorgio, R ., U . Volta and P . R . Gibson "Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?" Gut, 2016 . 65(1): 169-78 .
  48. Deding, U ., C . Torp-Pedersen and H . Bøggild "Perceived stress as a risk factor for dyspepsia: a register-based cohort study ." Eur Gastroenterol Hepatol, 2017 . 29(5): 560-567 .
  49. Deng, Y ., B . Misselwitz, N . Dai and M . Fox "Lactose Intolerance in Adults: Biological Mechanism and Dietary Management ." Nutrients, 2015 . 7(9): 8020-35 .
  50. Drossman, D . A . and W . L . Hasler “Rome IV-Functional GI Disorders: Disorders of GutBrain Interaction .” Gastroenterology, 2016 . 150(6): 1257–1261 .
  51. Drossman, D . A ., L . Chang, S . Schneck, C . Blackman, W . F . Norton and N . J . Norton "A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity ." Dig Dis SCi, 2009 . 54(7): 1532-41 .
  52. El-Ghazaly, M . A ., R . M . El-Hazek and M . T . Khayyal "Protective effect of the herbal preparation, STW 5, against intestinal damage induced by gamma radiation in rats" Int J Radiat Biol, 2015 . 91 (2): 150-6 .
  53. Enck, P ., F . Azpiroz, G . Boeckxstaens, S . Elsenbruch, C . Feinle-Bisset, G . Holtmann, J . M . Lackner, J . Ronkainen, M . Schemann, A . Stengel, J . Tack, S . Zipfel and N . J . Talley “Functional dyspepsia .” Nat Rev Dis Primers, 2017 . 3: 17081 .
  54. Enck, P ., Q . Aziz, G . Barbara, A . D . Farmer, S . Fukudo, E . A . Mayer, B . Niesler, E . M . Quigley, M . Rajilic-Stojanovic, M . Schemann, J . Schwille-Kiuntke, M . Simren, S . Zipfel and R . C . Spiller “Irritable bowel syndrome .” Nat Rev Dis Primers, 2016 . 2: 16014 .
  55. European Medicines Agency: EMEA/HMPC/263293/2006 - "Assessment repot on Foeniculum vulgare Miller subsp. vulgare Var. dulce (miller) Thellung, fructus ." Published 16 February 2010 . Available from: https://www.ema.europa.eu/en/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc_en.pdf .
  56. European Medicines Agency: EMA/HMPC/196746/2012 – “Assessment report on Melissa officinalis L ., folium .” Published 14 May 2013 . Available from: https://www .ema .europa .eu/documents/ herbal-report/final-assessment-report-melissa-officinalis-l-folium_en .pdf .
  57. European Medicines Agency: EMA/HMPC/294188/2013 – “Assessment report on Silybum marianum (L .) Gaertn ., fructus .” Published 5 June 2018 . Available from: https://www .ema .europa .eu/ documents/herbal-report/final-assessment-report-silybum-marianum-l-gaertn-fructus_en .pdf .
  58. European Medicines Agency: EMA/HMPC/369801/2009 – “Assessment report on Chelidonium majus L ., herba .” Published 13 September 2011 . Available from: https://www .ema .europa .eu/ documents/herbal-report/final-assessment-report-chelidonium-majus-l-herba_en .pdf .
  59. European Medicines Agency: EMA/HMPC/55837/2011 – “Assessment report on Matricaria recutita L ., flos and Matricaria recutita L ., aetheroleum .” Published 1 July 2014 . Available from: https:// www .ema .europa .eu/documents/herbal-report/draft-assessment-report-matricaria-recutita-l-flosmatricaria-recutita-l-aetheroleum_en .pdf .
  60. European Medicines Agency: EMA/HMPC/571122/2010 Corr . – “Assessment report on Glycyrrhiza glabra L . and/or Glycyrrhiza inflata Bat . and/or Glycyrrhiza uralensis Fisch ., radix .” Published 12 March 2013 . Available from: https://www .ema .europa .eu/documents/herbal-report/final-assessmentreport-glycyrrhiza-glabra-l/glycyrrhiza-inflata-bat/glycyrrhiza-uralensis-fisch-radix_en .pdf .
  61. European Medicines Agency: EMA/HMPC/614586/2012 – “Assessment report on Angelica sinensis (Oliv .) Diels, radix .” Published 9 July 2013 . Available from: https://www .ema .europa .eu/ documents/herbal-report/final-assessment-report-angelica-sinensis-oliv-diels-radix-first-version_en .pdf .
  62. European Medicines Agency: EMA/HMPC/715092/2013 – “European Union herbal monograph on Carum carvi L ., fructus .” Published 14 November 2014 . Available from: https://www .ema . europa .eu/documents/herbal-monograph/draft-european-union-herbal-monograph-carum-carvi-lfructus_en .pdf .
  63. European Medicines Agency: EMEA/HMPC/193910/2007 – “Assessment report on Mentha X piperita L ., folium .” Published 4 September 2008 . Available from: https://www .ema .europa .eu/documents/ herbal-report/assessment-report-mentha-x-piperita-l-folium_en .pdf .
  64. European Medicines Agency: EMEA/HMPC/246816/2005 – “Guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin .” Published 20 February 2006 . Available from: https://www .ema .europa .eu/documents/scientific-guideline/guideline-good-agriculturalcollection-practice-gacp-starting-materials-herbal-origin_en .pdf .
  65. Feinle-Bisset C . and F . Azpiroz "Dietary and lifestyle factors in functional dyspepsia ." Nat Rev Gastroenterol Hepatol, 2013 . 10(3): 150-7 .
  66. Filipović, B . F ., T . Randjelovic, N . Kovacevic, N . Milinić, O . Markovic, M . Gajić, B . R . Filipović "Laboratory parameters and nutritional status in patients with functional dyspepsia ." Eur J Intern Med, 2011 . 22(3): 300-4 .
  67. Flos Chamomillae, WHO monograph 2010.
  68. Folium Melissae, WHO monograph 2010.
  69. Folium Menthae Piperitae, WHO monograph 2002.
  70. Fond. G ., A . Loundou, N . Hamdani, W . Boukouaci, A . Dargel, J . Oliveira, M . Roger, R . Tamouza, M . Leboyer and L . Boyer "Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis ." Eur Arch Pyschiatry Clin Neurosci, 2014 . 264(8): 651-60 .
  71. Ford, A . C ., A . Marwaha, R . Sood and P . Moayeddi "Global prevalence of, and risk factors for, univestigated dyspepsia: a meta-analysis ." Gut, 2015 . 64(7): 1049-57 .
  72. Ford, A . C ., P . Moayyedi, B . E . Lacy, A . J . Lembo, Y . A . Saito, L . R . Schiller, E . E . Soffer, B . M . R . Spiegel, E . M . M . Quigley "American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation ." Am J Gastroenterol. 2014 . 109 Suppl 1: s2-26; quiz S27 .
  73. Fructus Silybi Mariae, WHO monograph 2002.
  74. Gabrielli, A . , E . V . Avvedimento and T . Krieg "Scleroderma ." N Engl J Med, 2009 . 360(19): 1989-2003 .
  75. Germann, I ., D . Hagelauer, O . Kelber, B . Vinson, S . Laufer, D . Weiser, H . Heinle "Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast)." Phytomedicine, 2006 . 13: p. 45-50.
  76. Ghisa, M ., M . D . Coletta, I . Barbuscio, E . Marabotto, B . Barberio, M . Frazzoni, N . De Bortoli, P . Zentilin, S . Tolone, A . Ottonello, G . Lorenzon, V . Savarino and E . Savarino "Updates in the field of non-esophageal gastroesophageal reflux disorder ." Expert Rev Gastroenterol Hepatol, 2019 . 13(9): 827-838 .
  77. Göktaş, Z ., S . Köklü, D . Dikmen, Ö . Öztürk, B . Yılmaz, M . Asıl, H . Korkmaz, Y . Tuna, M . Kekilli, E . K . Aksoy, H . Köklü, A . Demir, G . Köklü and S . Arslan " Nutritional habits in functional dyspepsia and its subgroups: a comparative study ." Scand J Gastroenterol, 2016 . 51(8): 903-7 .
  78. Gschossmann, J . M ., G . Holtmann and E . A . Mayer “[Epidemiology and clinical phenomenology of visceral pain] .” Schmerz, 2002 . 16(6): 447–451 .
  79. Gundermann, K . J ., E . Godehardt and M . Ulbrich “Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials .” Adv Ther, 2003 . 20(1): 43–49 .
  80. Hachem, C . and N . J . Shaheen "Diagnosis and Management of Functional Heartburn ." Am J Gastroenterol, 2016 . 111(1): 53-61 .
  81. Hagelauer, D ., O . Kelber, D . Weiser, S . Laufer and H . Heinle “Effects of Substance P and Neurotensin on the contractility of ileum of mice in vitro: Inhibition by plant extract STW 5 (Iberogast®) .” Planta Med, 2007 . 73(09): P_478 .
  82. Halmos, E . P ., C . T . Christophersen, A . R . Bird, S . J . Shepherd, P . R . Gibson and J . G . Muir "Diets that differ in their FODMAP content alter the colonic luminal microenvironment ." Gut, 2015 . 64(1): 93-100 .
  83. Halmos, E . P ., V . A . Power, S . J . Shepherd, P . R . Gibson and J . G . Muir "A diet low in FODMAPs reduces symptoms of irritable bowel syndrome ." Gastroenterology, 2014 . 146(1): 67-75 e5 .
  84. Hasler WL, Gas and Bloating, Gastroenterol Hepatol (N Y). 2006 Sep; 2(9): 654–66
  85. Hassanzadeh, S ., P . Saneei, A . H . Keshteli, H . Daghaghzadeh, A . Esmaillzadeh and P . Adibi "Meal frequency in relation to prevalence of functional dyspepsia among Iranian adults ." Nutrition, 2016 . 32(2): 242-8 .
  86. Hayes, P . A ., M . H . Fraher and E . M . M . Quigley "Irritable bowel syndrome: the role of food in pathogenesis and management ." Gastroenterol Hepatol (N Y), 2014 . 10(3): 164-74 .
  87. Herba Chelidonii, WHO monograph 2010.
  88. Hohenester, B ., A . Rühl, O . Kelber and M . Schemann “The herbal preparation STW5 (lberogast) has potent and region-specific effects on gastric motility .” Neurogastroenterol Motil, 2004 . 16(6): 765–773 .
  89. Hölscher, H. J. "Therapy of Non-specific Gastrointestinal Complaints in Elderly Patients" Therapiwoche, 1984 . 34: 657-659 .
  90. Holtmann, G ., A . Shah and M . Morrison “Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview .” Dig Dis, 2017 . 35 (Suppl 1): 5–13 .
  91. Holtmann, G ., D . Schrenk, A . Madisch, H . D . Allescher, G . Ulrich-Merzenich, F . Mearin, D . Larrey and P . Malfertheiner "Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Dirsorders: A conceptional Framework for Risk-Benefit Assessment and Regulatory approaches " Dig Dis, 2019 . online, DOI: 10.1159/000504570
  92. Holtmann, G ., N. J. Talley "Herbal medicines for the treatment of functional and inflammatory bowel disorders ." Clinical Gastroenterol Hepatol, 2015 . 13(3): 422-32.
  93. Houghton, L . A ., M . Heitkemper, M . Crowell, A . Emmanuel, A . Halpert, J . A . McRoberts and B . Toner “Age, Gender and Women's Health and the Patient .” Gastroenterology, 2016 . 150(6): 1332–1343 .e1334 .
  94. Iberis, Hager ROM 2003, Springer Verlag, Heidelberg 2003, HN: 2001400.
  95. Illing, G ., G . Sajthy "On the Antiemetic Effect of Iberogast® " Der Kassenarzt, 1984 . 24: 46-49 .
  96. Iovino, P ., C . Bucci, F . Tremolaterra, A . Santonicola and G . Chiarioni “Bloating and functional gastro-intestinal disorders: where are we and where are we going?” World J Gastroenterol, 2014 . 20(39): 14407–14419 .
  97. Jones, H . F ., R . N . Butler and D . A . Brooks "Intestinal dructose transport and malabsorption in humans ." Am J Physiol Gastrointest Liver Physiol, 2010 . 300: G202-G206 .
  98. Kelber, O ., B . Steinhoff, C . Nauert, A . Biller, M . Adler, H . Abdel-Aziz, S . N . Okpanyi, K . Kraft and K . Nieber “Ethanol in herbal medicinal products for children: Data from pediatric studies and pharmacovigilance programs .” Wien Med Wochenschr, 2017 . 167(7–8): 183–188 .
  99. Khayyal, M . T ., M . A . el-Ghazaly, S . A . Kenawy, M . Seif-el-Nasr, L . G . Mahran, Y . A . Kafafi and S . N . Okpanyi “Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination .” Arzneimittelforschung, 2001 . 51(7): 545–553 .
  100. Khayyal, M . T ., M . Abdel-Tawab, S . El-Sayed, B . Vinson and A . Abdel-Aziz "Effect of the herbal preparation, STW 5, on the microbiome in an experimental model of functional dyspepsia " Gastroenterology, 2017 . 152 (5): S1009 .
  101. Khayyal, M . T ., M . Seif-El-Nasr, M . A . El-Ghazaly, S . N . Okpanyi, O . Kelber and D . Weiser “Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast) and its components against ulcers and rebound acidity .” Phytomedicine, 2006 . 13 (Suppl 5): 56–66 .
  102. Klein-Galczinsky, C . and I . Sassin “P25: Post-marketing surveillance of the efficacy and tolerability of Iberogast for the therapy of colon irritabile .” German Soc Phytoth, 1999 . p 125 .
  103. Koduru, P ., M . Irani and E . M . M . Quigley "Definition, Pathogenesis, and Management of That Cursed Dyspepsia ." Clin Gastroenterol Hepatol, 2018 . 16(4): 467-479 .
  104. Kohlhoff, E ., U . Hübner-Steiner "Controlled Double-blind Study of Iberogast versus Placebo in the Treatment of Gastrointestinal Ailments due to Stress at the Workplace", Internal Study report: 8: Research Report No. 06/85 1-55 .
  105. Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19 .
  106. Lacy, B . E ., F . Mearin, L . Chang, W . D . Chey, A . J . Lembo, M . Simren and R . Spiller “Bowel Disorders .” Gastroenterology, 2016 . 150(6): 1393–1407 .e1395 .
  107. Lebwohl, B ., D . S . Sanders and P . H . R . Green "Coeliac disease ." Lancet, 2018 . 391(10115): 70-81 .
  108. Lindkvist, B . "Diagnosis and treatment of pancreatic exocrine insufficiency ." World J Gastroenterol, 2013 . 19(42): 7258-66 .
  109. Liquiritiae radix, ESCOP monographs 2003.
  110. Liu, C .-Y ., M . H . Müller, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine .” Neurogastroenterology & Motility, 2004 . 16(6): 759–764 .
  111. Lovell, R . M . and A . C . Ford “Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis .” Clin Gastroenterol Hepatol, 2012 . 10(7):712–721 .e4 .
  112. MacLean, N., U . Hübner-Steiner "Controlled Double-Blind Study of Iberogast verus Placebo for the Treatment of Gastrointestinal Complaints due to Drug Intolerance", Internal Study Report 7: Research Report No. 07/85 1-61 .
  113. MacLean, N., U. Hübner-Steiner "Controlled Double-Blind Study of Iberogast versus Placebo for the Treatment of Gastrointestinal Complaints due to Drug Intolerance", Internal Study Report 6: Research Report No. 06/86 1-49 .
  114. Madisch, A ., G . Holtmann, K . Plein and J . Hotz “Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial .” Aliment Pharmacol Ther, 2004 . 19(3): 271–279 .
  115. Madisch, A ., H . Melderis, G . Mayr, I . Sassin and J . Hotz “Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie .” Z Gastroenterol, 2001 . 39(07): 511–517 .
  116. Malfertheiner, P . "STW 5 (Iberogast) Therapy in Gastrointestinal Functional Disorders ." Dig Dis, 2017 . 35: 25-29.
  117. Manuyakorn, W . and P . Tanpowpong "Cow milk protein allergy and other common food allergies and intolerances ." Paediatr Int Child Health, 2019 . 39(1): 32-40 .
  118. Marx, L ., D . Grundmann, S . Dominik, M . Klotz, D . Simon, H . Rabe, H . Abdel-Aziz, O . Kelber and K .-H . Schäfer “Influences of STW 5, a multi-component herbal preparation, on motility and inflammation challenges in gut and enteric nervous system (ENS) .” Digestive Disease Week 2016 . San Diego Convention Center, 2016 .
  119. Marzio, L ., M . Falcucci, L . Grossi, F . A . Ciccaglione, M . G . Malatesta, A . Castellano and E . Ballone “Proximal and distal gastric distension in normal subjects and H . pylori-positive and -negative dyspeptic patients and correlation with symptoms .” Dig Dis Sci, 1998 . 43(12): 2757–2763 .
  120. Matricariae flos, ESCOP monographs 2003.
  121. Mayer, E . A ., S . Bradesi, L . Chang, B . M . R . Spiegel. J . A . Bueller and B . D . Naliboff "Functional GI disorders: from animal models to drug development ." Gut, 2008 . 57(3): 384-404 .
  122. Melissae folium, ESCOP monographs 2013.
  123. Melzer, J ., W . Rosch, J . Reichling, R . Brignoli and R . Saller “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast) .” Aliment Pharmacol Ther, 2004 . 20(11-12): 1279–1287 .
  124. Menthae piperitae folium, ESCOP monographs 2019.
  125. Metz, A . and G . Hebbard "Nausea and vomiting in adults--a diagnostic approach ." Aust Fam Physician, 2007 . 36(9): 688-92 .
  126. Michael, S ., H . Abdel-Aziz, D . Weiser, C . E . Muller, O . Kelber and K . Nieber “Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast(R)) in rat small intestinal preparations .” Naunyn Schmiedebergs Arch Pharmacol, 2012 . 385(4): 411–421 .
  127. Michael, S ., O . Kelber, S . Hauschildt, K . divel-Borowski and K . Nieber “Inhibition of inflammation-induced alterations in rat small intestine by the herbal preparations STW 5 and STW 6 .” Phytomedicine, 2009 . 16(2-3): 161–171 .
  128. Michaudet, C . and J . Malaty "Chronic Cough: Evaluation and Management ." Am Fam Physician, 2017 . 96(9): 575-580 .
  129. Moayyedi, P ., E . M . M . Quigley, B . E. Lacy, A . J . Lembo, Y . A . Saito, L . R . Schiller, E . E . Soffer, B . M . R . Spiegel and A . C . Ford "The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis ." Am J Gastroenterol, 2014 . 109(9): 1367-74 .
  130. Mueller, M . H ., H . Seeliger, N . Hering, M . S . Kasparek, A . H . Abdel and M . E . Kreis “Differential Desensitisation of Afferent Nerve Fibres by Iberis amara (STW 6) and Iberogast (STW 5) in the Murine Colon .” Am J Phytomed Clin Ther, 2018 . 6(1:4) .
  131. Mullan, A ., P . Kavanagh, P . O'Mahony, T . Joy, F . Gleeson and M . J . Gibney "Food and nutrient intakes and eating patterns in functional and organic dyspepsia ." Eur J Clin Nutr, 1994 . 48(2): 97-105 .
  132. Müller, M . H ., C . Y . Liu, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “STW 5 (Iberogast) reduces afferent sensitivity in the rat small intestine .” Phytomedicine, 2006 . 13 (Suppl 5): 100–106 .
  133. Ness-Jensen, E ., K . Hveem, H . El-Serag and J . Lagergren "Lifestyle Intervention in Gastroesophageal Reflux Disease ." Clin Gastroenterol Hepatol, 2016 . 14(2): 175-82.e1-3 .
  134. Nicolay, K . "Metoclopramide versus the Herbal Medicine Iberogast® in the Treatment of Functional Gastroenteropathies" Gastro-Entero-Hepatologie, 1984. 2:1-12.
  135. Nieber, K ., V . Winkelmann, S . Hoser, O . Kelber, H . Abdel-Aziz and D . Weiser “Evaluation of the cytoprotective effects of individual and combined constituents of the herbal drug STW 5 .” Planta Medica, 2012 . 78(11):1086
  136. Ohms, P . "Tablets Every Day: How Long can the Stomach Tolerate it? " Ärztl. Praxis, 1983 . 35: 3109-3110.
  137. Okpanyi, S . N . “Acute oral toxicity of Iberogast® (STW 5) in the rat .” 1986 . STW FB 17/86 .
  138. Okpanyi, S . N . “Acute oral toxicity of Iberogast® in the mouse .” 1986 . STW FB 18/86 .
  139. Ottilinger, B ., M . Storr, P . Malfertheiner, H . D . Allescher "STW 5 (Iberogast -- a safe and effective standard in the treatment of functional gastrointestinal disorders ." Wien Med Wochenschr, 2013. 163(3-4): 65-72 .
  140. Patti, M . G ., H . I . Goldberg, M . Arcerito, L . Bortolasi, J . Tong and L . W . Way "Hiatal hernia size affects lower esophageal sphincter function, esophageal acid exposure, and the degree of mucosal injury ." Am J Surg, 1996 . 171(1): 182-6 .
  141. Pilichiewicz, A . N ., M . Horowitz, A . Russo, A . F . Maddox, K . L . Jones, M . Schemann, G . Holtmann and C . Feinle-Bisset “Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men .” Am J Gastroenterol, 2007 . 102(6): 1276–1283 .
  142. Radix Glycyrrhizae, WHO monograph 2010.
  143. Raedsch, R ., B . Vinson, B . Ottillinger and G . Holtmann “Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: A noninterventional study with Iberogast(R) .” Wien Med Wochenschr, 2018 . 168(3–4): 89–98 .
  144. Raedsch, R ., J . Hanisch, P . Bock, A . Sibaev, B . Vinson and K . J . Gundermann “Wirksamkeit und Unbedenklichkeit des Phytopharmakons STW 5 versus Metoclopramid bei funktioneller Dyspepsie unter Praxisbedingungen - eine retrolektive Kohortenstudie .” Z Gastroenterol, 2007 . 45(10): 1041–1048 .
  145. Rajindrajith, S ., J . Zeevenhooven, N . M . Devanarayana, B . J . C . Perera and M . A . Benninga "Functional abdominal pain disorders in children ." Expert Rev Gastroenterol Hepatol, 2018 . 12(4): 369-390 .
  146. Rasmussen, S ., T . H . Jensen, S . L . Henriksen, P . F . Haastrup, P . V . Larsen, J . Sondergaard and D . E . Jarbol “Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population .” Scand J Gastroenterol, 2015 . 50(2): 162–169 .
  147. Reichling, J . and R . Saller “Iberis amara L . (Bittere Schleifenblume) – Profil einer Heilpflanze .” Forsch Komplementärmed Klass Naturheilkd, 2002 . 9: 21–33 .
  148. Richter, J . E . "Gastroesophageal reflux disease in the older patient: presentation, treatment, and complications ." Am J Gastroenterol, 2000 . 95(2): 368-73 .
  149. Rösch, W ., B . Vinson and I . Sassin “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia .” Z Gastroenterol, 2002 . 40(6): 401–408 .
  150. Saito, Y . A ., G . M . Petersen, J . J . Larson, E . J . Atkinson, B . L . Fridley, M . de Andrade, G . R . Locke 3rd, J . M . Zimmerman, A . E . Almazar-Elder and N . J . Talley "Familial aggregation of irritable bowel syndrome: a family case-control study ." Am J Gastroenterol, 2010 . 195(4): 833-41 .
  151. Sassin, I . and D . Buchert “Efficacy and tolerability of the herbal prepararion Iberogast® in the therapy of Functional Dyspepsia .” Phytomedicine, 2000 . 7(Suppl . II): 91–92 .
  152. Schemann, M ., K . Michel, F . Zeller, B . Hohenester and A . Ruhl “Region-specific effects of STW 5 (Iberogast) and its components in gastric fundus, corpus and antrum .” Phytomedicine, 2006 . 13 (Suppl 5): 90–99 .
  153. Schempp, H ., A . Toth, D . Weiser, E . F . Elstner "Antioxidative properties of Iberis amara extracts in biochemical model reactions ." Arzneimittelforschung, 2003 . 13677247
  154. Schempp, H ., D . Weiser, O . Kelber and O . Elstner "Radical scavenging and anti-inflammatory properties of STW 5 (Iberogast) and its components ," Phytomedicine, 2006 . 13 Suppl 5:36-44 .
  155. Schempp, H ., S . Hippeli, D . Weiser, O . Kelber, E . F . Elstner "Comparison of the inhibition of myeloperoxidase-catalyzed hypochlorite formation in vitro and in whole blood by different plant extracts contained in a phytopharmacon treating functional dyspepsia ." Arzneimittelforschung, 2004 . 54(7):389-95 .
  156. Schiller, L . R . "Maldigestion Versus Malabsorption in the Elderly ." Curr Gastroenterol Rep, 2020 . 22(7): 33 .
  157. Schneider, M ., T . Efferth and H . Abdel-Aziz “Anti-inflammatory Effects of Herbal Preparations STW5 and STW5-II in Cytokine-Challenged Normal Human Colon Cells .” Front Pharmacol, 2016 . 7: 393 .
  158. Schoenmakers A . C . M ., W . J . A . M . Frieling and C . J . Mitchell “STW 5 (Iberogast®): Combined 3 and 6-month oral gavage toxicity study in male and female Wistar rats followed by a one-month recovery period .” 2003 . Notox project no . 330211 .
  159. Sibaev, A ., H . Abdel-Aziz, O . Kelber, H . D . Allescher and M . Storr “Mechanism of action of STW 5 and its components on motility and intestinal neurotransmission in “in vitro” model of the human colon .” Neurogastroenterol Motil, 2015 . 27 (Suppl . 2): 101 .
  160. Sierra, D ., M . Wood, S . Kolli and L . M . Felipez "Pediatric Gastritis, Gastropathy, and Peptic Ulcer Disease ." Pediatr Rev, 2018 . 39(11): 542-549 .
  161. Silybi mariani fructus, ESCOP monographs 2009.
  162. Simmen, U ., O . Kelber, R . Jaeggi, B . Büter, S . N . Okpanyi and D . Weiser . “Relevance of the herbal combination of STW 5 for its binding affinity to the muscarinic M3 receptor .” Naunyn Schmiedeberg´s Arch Pharmacol, 2003 . 367, (Suppl 1): R22 .
  163. Simmen, U ., O . Kelber, S . N . Okpanyi, R . Jaeggi, B . Bueter and D . Weiser “Binding of STW 5 (Iberogast®) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors .” Phytomedicine, 2006 . 13: 51–55 .
  164. Sporrer, M . "Rapidly Effective Phytotherapy in Gastrointestinal Complaints " Medica - Seminarzeitschrift für die ärztliche Praxis, 1984 . 5
  165. Stanghellini, V ., F . De Ponti, R . De Giorgio, G . Barbara, C . Tosetti and R . Corinaldesi “New developments in the treatment of functional dyspepsia .” Drugs, 2003 . 63(9): 869–892 .
  166. Stanghellini, V ., F . K . Chan, W . L . Hasler, J . R . Malagelada, H . Suzuki, J . Tack and N . J . Talley “Gastroduodenal Disorders .” Gastroenterology, 2016 . 150(6): 1380–1392 .
  167. Steimer, P . "Iberogast® Therapy in Gastroenterology - Therapeutic Experience Report ." Der Krankenhausarzt, 1983. Vol. 12: 1005-1008 .
  168. Surdea-Blaga, T ., D . E . Negrutiu, M . Palage and D . L . Dumitrascu "Food and Gastroesophageal Reflux Disease ." Curr Med Chem, 2019 . 26(19): 3497-3511 .
  169. Tack, J ., H . Piessevaux, B . Coulie, P . Caenepeel and J . Janssens “Role of impaired gastric accommodation to a meal in functional dyspepsia .” Gastroenterology, 1998 . 115(6): 1346–1352 .
  170. Tack, J ., I . Demedts, G . Dehondt, P . Caenepeel, B . Fischler, M . Zandecki and J . Janssens “Clinical and pathophysiological characteristics of acute-onset functional dyspepsia .” Gastroenterology, 2002 . 122(7): 1738–1747 .
  171. Tack, J ., P . Caenepeel, B . Fischler, H . Piessevaux and J . Janssens “Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia .” Gastroenterology, 2001 . 121(3): 526–535 .
  172. Talley, N . J . and A . C . Ford "Functional Dyspepsia ." N Engl J Med, 2015 . 373(19): 1853-63 .
  173. Talley, N . J ., M . M . Walker and G . Holtmann “Functional dyspepsia .” Curr Opin Gastroenterol, 2016 . 32(6): 467–473 .
  174. Thélin, C . S . and J . E . Richter "Review article: the management of heartburn during pregnancy and lactation ." Aliment Pharmacol Ther, 2020 . 51(4): 421-434 .
  175. Thumshirn, M . “Pathophysiology of functional dyspepsia .” Gut, 2002 . 51 (Suppl 1): i63-66 .
  176. Tullmann, D . F . and K . Dracup "Knowledge of heart attack symptoms in older men and women at risk for acute myocardial infarction ." J Cardiopulm Rehabil, 2005 . 25(1): 33-9 .
  177. Ulrich-Merzenich, G ., L. Welslau, H. Aziz-Kalbhenn, O. Kelber, A. Shcherbakova "Synergy quantifications to identify individual contributions of combination partners to the overall activity - The example of STW 5 ." Phytomedicine, 2019. 16: 153013 .
  178. Van Oudenhove, L . and Q . Aziz "The role of psychosocial factors and psychiatric disorders in functional dyspepsia ." Nat Rev Gastroenterol Hepatol, 2013 . 10(3): 158-67 .
  179. van Rozendaal, A . W . M ., W . J . A . M . Frieling and C . J . Mitchell “STW 5 (Iberogast®): 3-Month oral gavage toxicity study in male and female Beagle dogs followed by a 1-month recovery period .” 2003, Notox project no . 330222 .
  180. van Rozendaal, A . W . M ., W . J . A . M . Frieling and C . J . Mitchell “STW 5 (Iberogast®): Acute oral toxicity study in male and female Wistar rats .” 2003, Notox project no . 320265 .
  181. Vazquez-Roque, M . I ., M . Camilleri, T . Smyrk, J . A . Murray, E . Marietta, J . O'Neill, P . Carlson, J . Lamsam, D . Janzow, D . Eckert, D . Burton and A . R . Zinsmeister "A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function ." Gastroenterology, 2013 . 144(5): 903-911 e3 .
  182. Vinson, B . and G . Holtmann “Mo1885 A Survey of Treatment of Patients With Functional Dyspepsia in the Routine Clinical Setting .” Gastroenterology, 2013 . 144(5): S–683 .
  183. Vinson, B . and M . Radke “The herbal preparation STW 5 for the treatment of functional gastrointestinal diseases in children aged 3–14 years – a prospective non interventional study .” Digestive disease week, Chicago, IL, USA ., 2011 . Abstract #523 .
  184. Völkner, W ., M . Arenz, F . Hermann and H . G . Miltenburger “In vivo/in vitro unscheduled DNA synthesis in rat hepatocytes with STW 5 .” CCR Cytotest Cell Research GmbH & Co . KG, Roßdorf/ Germany, Test Report 1996 . CCR project no: 538203 .
  185. Völkner, W ., M . Arenz, F . Hermann and H . G . Miltenburger “Micronucleus assay in bone marrow cells of the mouse with STW 5 . Test report, Proj . No . 538 204 .” CCR Cytotest Cell Research GmbH & Co . KG, Roßdorf/Germany, Test Report 1996 . CCR project no: 538104 .
  186. Völkner, W ., M . Arenz, F . Hermann and H . G . Miltenburger “Micronucleus assay in bone marrow cells of the mouse with STW 5 .” CCR Cytotest Cell Research GmbH & Co . KG, Roßdorf/Germany . Test Report 1996 . CCR project no: 538204 .
  187. von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .
  188. Voß, U ., F . Herr, N . Störmer, S . Okpanyi, D . Weiser, O . Kelber, H . Abdel-Aziz and K . Nieber, “Effects of STW 5, STW 5II and their components on contractility of inflamed rat colon preparations .” Young Researchers Meeting . Münster, 2012 .
  189. Wadie, W ., H . Abdel-Aziz, H . F . Zaki, O . Kelber, D . Weiser and M . T . Khayyal “STW 5 is effective in dextran sulfate sodium-induced colitis in rats .” Int J Colorectal Dis, 2012 . 27(11): 1445–1453 .
  190. Wagner, H . "Multitarget therapy - The future of treatment for more than just functional dyspepsia ." Phytomed, 2006 . 13 SV 122-129
  191. Wagner, H . "Multitarget therapy - The future of treatment for more than just functional dyspepsia ." Phytomedicine, 2006 . 5: 122-9 .
  192. Wald, K ., O . Kelber, D . Weiser, S . Laufer, H . Heinle "Antioxidant properties of STW 5 and its single extracts on histamine-induced radical production of murine ileum ." Z Phytother, 2009 . 30(Suppl. 1): p. S36.
  193. Wallace, J . L . "Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?" Physiol Rev, 2008 . 88(4): 1547-65 .
  194. Wang, Y . P ., C . C . Herndon and C . L . Lu "Non-pharmacological Approach in the Management of Functional Dyspepsia ." J Neurogastroenterol Motil, 2020 . 26(1): 6-15 .
  195. Wingate, D ., M . Hongo, J . Kellow, G . Lindberg and A . Smout “Disorders of gastrointestinal motility: towards a new classification .” J Gastroenterol Hepatol, 2002 . 17 (Suppl): S1-14 .
  196. Wong, Y ., D . M . H . Freeland, K . C . Nadeau "Food allergy: immune mechanisms, diagnosis and immunotherapy ." Nat Rev Immunol, 2016 . 16(12): 751-765 .
  197. Yu, H . X ., C . S . Han, J . R . Xue, Z . F . Han and H . Xin "Esophageal hiatal hernia: risk, diagnosis and management ." Expert Rev Gastroenterol Hepatol, 2018 . 12(4): 319-329 .
  198. Zhou, C ., E . Zhao, Y . Li, Y . Jia and F . Li "Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials ." Neurogastroenterol Motil, 2019 . 31(2):e13461 .
Butelka Iberogast stojąca na mchu, obok opakowania, w otoczeniu lasu.

Iberogast®

Zaburzenia ze strony przewodu pokarmowego są zazwyczaj nie tylko wyjątkowo nieprzyjemne i związane z licznymi dolegliwościami, ale często utrudniają codzienne życie. Całe szczęście istnieje Iberogast®: połączenie dziewięciu ziół leczniczych5, 45, 98, 105 skoncentrowane na walce zarówno z podstawowymi przyczynami5, 8, 10, 130, 191, jak i irytującymi objawami23, 28, 45, 79, 114, 115, 123, 149, 187.

Wszystko o Iberogast®

Bibliografia

Butelka leku Iberogast® na zielonym tle, w otoczeniu ziół.

Korzystaj z potęgi natury we własnym domu!

Sprawdź, gdzie można kupić lek Iberogast w dobrej cenie.

Przed użyciem zapoznaj się z ulotką, która zawiera wskazania, przeciwwskazania, dane dotyczące działań niepożądanych i dawkowanie oraz informacje dotyczące stosowania produktu leczniczego, bądź skonsultuj się z lekarzem lub farmaceutą, gdyż każdy lek niewłaściwie stosowany zagraża Twojemu życiu lub zdrowiu.